Developer · CLN · Poland

Celon Pharma S.A.

Polish pharmaceutical company headquartered in Kazun Nowy near Warsaw, listed on the Warsaw Stock Exchange (WSE: CLN). Combines a generics business with an in-house innovative R&D pipeline; its CNS assets include the PDE10A inhibitor alofropodect (CPL'36 / CPL500036) for schizophrenia and levodopa-induced dyskinesia, and Falkieri (inhaled esketamine) for treatment-resistant depression.

celonpharma.com ↗

1compound
2programs
2indications
Phase 2lead asset

Phase distribution

  • Phase 22

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Catalysts · 0 upcoming · 3 reported

Recently reported

  • 2026-07-31met

    AlofropodectforSchizophreniaFull results

    Peer-reviewed Phase 2 results published in CNS Drugs: both doses met the PANSS positive primary endpoint (-3.70 and -6.35 vs placebo); response rate (>=30% PANSS total reduction) 3.8% placebo, 15.4% 20 mg, 42.3% 40 mg.

    source ↗

  • 2025-03-04met

    AlofropodectforLevodopa-induced dyskinesia in Parkinson's diseaseTopline data

    Phase 2 in levodopa-induced dyskinesia (n=105) met its primary endpoint: CPL'36 improved UDysRS total by 12.30 (20 mg) and 13.58 (40 mg) units vs placebo (both p<0.001).

    source ↗

  • 2024-07-05met

    AlofropodectforSchizophreniaTopline data

    Phase 2 in acute schizophrenia (n=189) met its primary endpoint: CPL'36 improved PANSS positive by 3.7 (20 mg) and 6.3 (40 mg) points vs placebo, and PANSS total by 9.7 and 16.4 points (all p<0.001).

    source ↗

Recent activity

  • Jul 31, 2026ReadoutAlofropodect·SchizophreniametPeer-reviewed Phase 2 results published in CNS Drugs: both doses met the PANSS positive primary endpoint (-3.70 and -6.35 vs placebo); response rate (>=30% PANSS total reduction) 3.8% placebo, 15.4% 20 mg, 42.3% 40 mg.source ↗
  • Oct 8, 2025Phase changeAlofropodect·SchizophreniaPhase 2Celon announced positive FDA feedback from a Type B meeting: existing preclinical data are sufficient to start pivotal studies; the FDA endorsed a Phase 3 program of two 28-day acute trials plus a 12-month open-label extension. Celon expects to start pivotal studies in 2026. Program kept at phase_2 until a Phase 3 trial starts.source ↗
  • Mar 4, 2025ReadoutAlofropodect·Levodopa-induced dyskinesia in Parkinson's diseasemetPhase 2 in levodopa-induced dyskinesia (n=105) met its primary endpoint: CPL'36 improved UDysRS total by 12.30 (20 mg) and 13.58 (40 mg) units vs placebo (both p<0.001).source ↗
  • Jan 27, 2025Phase changeAlofropodect·Levodopa-induced dyskinesia in Parkinson's diseasePhase 2NCT05297201 completed (primary completion 2025-01-13, study completion 2025-01-27) with 105 participants enrolled.source ↗
  • Jul 5, 2024ReadoutAlofropodect·SchizophreniametPhase 2 in acute schizophrenia (n=189) met its primary endpoint: CPL'36 improved PANSS positive by 3.7 (20 mg) and 6.3 (40 mg) points vs placebo, and PANSS total by 9.7 and 16.4 points (all p<0.001).source ↗
  • Jun 19, 2024Phase changeAlofropodect·SchizophreniaPhase 2NCT05278156 completed (primary completion 2024-06-05, study completion 2024-06-19), 189 participants enrolled.source ↗
  • Nov 2, 2021Phase changeAlofropodect·Levodopa-induced dyskinesia in Parkinson's diseasePhase 2Phase 2 randomised, placebo-controlled study NCT05297201 in levodopa-induced dyskinesia started (CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in UDysRS total score at Week 4).source ↗
  • May 19, 2021Phase changeAlofropodect·SchizophreniaPhase 2Phase 2 randomised, double-blind, placebo-controlled study NCT05278156 in acute schizophrenia started (189 patients; CPL500036 20 mg or 40 mg once daily vs placebo for 28 days; primary endpoint change in PANSS positive subscale at Day 28).source ↗
  • Sep 16, 2019Phase changeAlofropodect·SchizophreniaPhase 1First-in-human single and multiple ascending dose study in healthy volunteers (NCT03873324, 56 participants, Poland) completed; started 2018-12-20.source ↗

Competitive landscape

Other companies developing against Celon Pharma S.A.'s targets or indications.